Our Transitions: Improving the Path to Menopause With Personal Digital Health Technologies
14 maja 2026 zaktualizowane przez: 4YouandMe
The goal of this observational study is to build knowledge about the path to menopause using subjective, self-reported and objectively measured information from multiple wearable study devices and a smartphone app.
This study is being done in female individuals who are 35-55 years of age.
The eventual aim of this work is two-fold; 1) to increase knowledge, awareness and education for individuals and clinicians about the lived experience of perimenopause and menopause through objectively measured data from digital study devices, and 2) to develop approaches to empower female individuals to manage this transition by learning what improves or worsens their symptoms.
Przegląd badań
Status
Jeszcze nie rekrutacja
Warunki
Szczegółowy opis
The ultimate objective of this research is to determine the feasibility of using multiple wearable study devices and smartphone apps to detect, track and learn how to share insights about symptoms during the path to menopause.
The investigators anticipate that up to 250 participants will participate for 6 to 9 months.
Participants will complete surveys and active tasks in a study app that takes on average 5 minutes a day, be provided with an Oura Ring Gen 4 and a Fitbit Sense 2 and will be expected to wear them daily.
Participants will be expected to check in with a research coordinator every two weeks to go over participations and provide feedback on the wearable devices and smartphone apps.
A subset of participants will be invited to participate in an at-home daily urine hormone collection for 3 menstrual cycles, measuring hormones including Luteinizing Hormone (LH), Estrone-3-glucuronide (E3G), and Pregnanediol Glucuronide (PdG).
A different subset will be invited to participate in a vasomotor detection cohort using the new Vire Clip that captures core body temperature through heat flow, the dynamics of respiratory effort, and skin conductance measures at multiple layers of the skin.
There will be a 'Bring Your Own Device' cohort after the main cohort enrollment is complete, where those with a personal wearable device will be invited to participate in the use of the study app for 6 to 9 months.
Investigators will collect self-reported subjective symptoms and objectively measured physiological information to understand what participants learn about the use of these tools in tracking peri/menopausal symptoms.
This study is done in collaboration between 4YouandMe, Women Living Better, Vector Institute, and is funded by the Steven and Alexandra Cohen Foundation.
Typ studiów
Obserwacyjny
Zapisy (Szacowany)
1250
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Kontakt w sprawie studiów
- Nazwa: Sarah Goodday, PhD
- Numer telefonu: 902-237-4235
- E-mail: sarah@4youandme.org
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Nie dotyczy
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
Eligible participants will live in the US or Canada.
Up to 250 participants will be invited to participate in the main cohort, 75 in the hormone sub-cohort, and 70 in the Vire clip sub-cohort.
Opis
Inclusion Criteria:
- Are 35-55 years old
- Reside in the US or Canada
- Are able to speak, write, and read English
- Are able to provide informed consent
- Have a personally owned iPhone (iOS Version 16.4)
Exclusion Criteria:
- Are not willing to wear a wearable study device
- Have a hormonal intrauterine device (IUD)
- Are taking birth control pills
- Are taking systemic estrogen or progesterone
- Have been diagnosed with Polycystic ovary syndrome (PCOS)
- Are taking the following medications (cancer treatment that affects the menstrual cycle, thyroid medication)
- Have had the following procedures (hysterectomy [removal of uterus], bilateral, oophorectomy [removal of both ovaries], endometrial ablation [surgery that destroys the lining of the uterus])
- Are currently pregnant, attempting to conceive, recently pregnant and not yet cycling and currently breast feeding
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Main Cohort
Up to 250 participants aged 35-55 years old, residing in the US or Canada, who will be asked to complete surveys and active tasks in a study app, and use the Oura Ring Gen 4 and Fitbit Sense 2 daily.
Participants will meet with research coordinators every 2 weeks to help support participation efforts and collect information on how the study and device use are going.
|
|
Hormone Sub-Cohort
A sub-cohort of up to 75 participants will be invited to participate in a hormone sub-cohort.
If the participant agrees to participate in this sub-cohort, they will be asked to complete daily at-home urine hormone samples provided to them for 3 consecutive menstrual cycles.
The hormone sub-cohort procedure consists of peeing on a disposable urine test strip in the morning and then using a digital analyzer to produce the results, measuring Luteinizing Hormone (LH), Estrone-3-glucuronide (E3G), and Pregnanediol Glucuronide (PdG).
|
|
Bring Your Own Device (BYOD) Open Arm
Once enrollment is complete in the main arm, and if the participant owns their own personal wearable device that includes an Oura ring, a Garmin smartwatch, Applewatch or Fitbit, they may be able to participate in the BYOD arm where they will participate by using the study app and providing the study investigators access to their wearable data.
They will be asked permission for this wearable data sharing when they first download the study app during a number of opt-in screens.
Up to 1000 participants may be enrolled in the BYOD arm.
|
|
Vire Clip Vasomotor Detection Sub-Cohort
A subset of up to 70 participants will be invited to participate in a vasomotor detection cohort that will involve the use of a new wearable (Vire) clip capable of capturing core body temperature through heat flow, the dynamics of respiratory effort, and skin conductance measures at multiple layers into the skin.
We want to learn whether these new wearable-derived signals could be used to detect when a vasomotor event will occur, like a hot flash, night sweat, cold sweat or feelings of sudden heating.
If you meet certain eligibility criteria, you will be mailed the Vire clip and given instructions on how to set it up and sync with the study app.
The Vire clip is a small clip that can be clipped onto the inside of your underwear.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Feasibility: Retention
Ramy czasowe: From enrollment to the end of participation at 12 months
|
Proportion of participants retained according to study protocol
|
From enrollment to the end of participation at 12 months
|
|
Feasibility: Adherence
Ramy czasowe: From enrollment to the end of participation at 12 months
|
Mean adherence to completing in-app daily study measures
|
From enrollment to the end of participation at 12 months
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Współpracownicy
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
1 maja 2026
Zakończenie podstawowe (Szacowany)
31 sierpnia 2027
Ukończenie studiów (Szacowany)
31 sierpnia 2027
Daty rejestracji na studia
Pierwszy przesłany
14 maja 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
14 maja 2026
Pierwszy wysłany (Rzeczywisty)
20 maja 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
20 maja 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
14 maja 2026
Ostatnia weryfikacja
1 maja 2026
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- PRO-OT2025
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .